Highest-materiality recent filing
Teva Q2 revenues $4.1B, GAAP loss $0.49/share; raises 2026 outlook for key innovative brands
Q2 revenues $4.1B (-1% YoY); GAAP loss per share $0.49; non-GAAP diluted EPS $0.02 (includes $0.61 Emalex impact).
Teva Q1 revenues $4.0B (+2% YoY); AUSTEDO up 41%; to acquire Emalex for $700M cash
Q1 GAAP diluted EPS $0.31; Non-GAAP diluted EPS $0.53; revenues $3,982M (+2% USD, -3% LC).
Teva posts FY 2025 revenue $17.3B (+4% YoY), non-GAAP EPS $2.93, guides FY26 rev $16.4-16.8B
FY 2025 revenues $17.3B (+4% YoY); GAAP diluted EPS $1.21, non-GAAP diluted EPS $2.93.
Teva pre-announces 2025 revenue $16.8-$17.0B, raises guidance; projects 2030 mid-single-digit CAGR
Expected 2025 revenue $16.8-$17.0B (low end), adjusted EBITDA $4.8-$5.0B (midpoint).
Teva extends revolving credit facility maturity to April 2028, adjusts leverage covenants
Maturity extended from April 2027 to April 2028 via second one-year extension of the revolving facility.
Teva Q3 2025: revenue $4.48B (+3%), non-GAAP EPS $0.78; Austedo outlook raised; TAPI sale restart
Revenue $4.48B (+3% YoY); GAAP EPS $0.37, non-GAAP EPS $0.78 (vs $0.69 YoY).
Teva Q2 2025 Non-GAAP EPS $0.66 (+9% YoY); Raises 2025 Innovative Product Revenue Outlook
Revenues $4.176B flat YoY; GAAP EPS $0.24; Non-GAAP EPS $0.66 (up from $0.61).
Teva issues €1B and $1.2B in senior notes to refinance debt, upsizes tender offer to $2.25B
€1B of 4.125% Senior Notes due 2031; $500M of 6.000% notes due 2032; $700M of 5.750% notes due 2030.
Teva Q1 2025: revenue $3.9B (+5% LC), Non-GAAP EPS $0.52 (+8% YoY); raises FY outlook
Q1 revenue $3.9B (+5% local currency, +2% reported); GAAP EPS $0.18, Non-GAAP EPS $0.52 (vs $0.48 YoY).
Teva FY2024 revenue $16.5B, GAAP EPS loss $1.45; non-GAAP EPS $2.49; sees 2025 rev $16.8-17.4B
FY2024 revenues $16.5B, +4% USD (+6% local currency); GAAP net loss $1.639B ($1.45/share) vs $559M loss in FY2023.
Teva Q3 rev $4.3B (+13% YoY); raises FY2024 guidance; Austedo $435M (+28%)
Q3 revenues $4.3B (+13% USD, +15% local currency); Non-GAAP diluted EPS $0.69 vs $0.60 YoY.
Teva Q2 revenue $4.2B +7%, non-GAAP EPS $0.61, raises full-year 2024 guidance
Revenue $4.2B (+7% USD, +11% local currency); GAAP loss $0.75/share, non-GAAP EPS $0.61.
Teva settles Israeli tax dispute for ~$750M over 2008-2020, plus up to $500M contingent
Teva to pay ~$750M to Israeli Tax Authorities over 2024-2029 for tax years 2008-2020.
Teva Q1 revenue $3.8B (+4% YoY), non-GAAP EPS $0.48, reaffirms FY24 guidance
Revenue $3.819B (+4% YoY, +5% local currency); generics up 9% globally.
Teva realigns reporting segments; Canada moved to International Markets from North America
Canada will be reported as part of International Markets segment, not North America, effective Q1 2024.
Full-year 2023 revenues $15,846M, up 7% in local currency; Q4 revenues $4,465M.
Teva Q3 revenue up 7% to $3.9B, raises FY revenue guidance to $15.1-$15.5B
Revenue $3.85B (+7% YoY); GAAP EPS $0.07, non-GAAP EPS $0.60.
Teva and Sanofi partner on anti-TL1A therapy TEV-574 for IBD; $500M upfront
Teva receives €469M ($500M) upfront and up to €940M ($1B) in development/launch milestones.
Teva appoints Christine Fox as EVP U.S. Commercial; Sven Dethlefs departing Nov 17
Sven Dethlefs, EVP North America Commercial, to leave Teva on November 17, 2023 after 15 years.
Teva settles DOJ price-fixing charges with $225M fine, DPA; avoids federal exclusion
Teva enters Deferred Prosecution Agreement with DOJ over 2020 price-fixing charges for generic drugs.
Teva Q2 2023 revenue $3.88B, GAAP loss $0.77/sh, non-GAAP EPS $0.56; raises revenue guidance
Revenue $3.88B (+2% YoY, +4% local currency); AUSTEDO U.S. rev $308M.
Teva will pay up to $4.25B over 13 years, including $1.2B of generic Narcan (or $240M cash) to participating states and subdivisions.
Teva Q1 revenue $3.7B flat YoY; non-GAAP EPS $0.40 down from $0.55; reaffirms FY 2023 outlook
Revenues $3,661M flat YoY (up 4% local currency); GAAP loss per share ($0.18) improved from ($0.86).
Teva issues €1.3B and $1.1B senior notes at 7.375%-8.125% to fund $2.5B tender offer
Issued €800M 7.375% '29 notes and €500M 7.875% '31 notes; plus $600M 7.875% '29 and $500M 8.125% '31 notes.
Teva prices $2.49B sustainability-linked senior notes; upsizes tender offer to $2.5B
Priced €800M 7.375% notes due 2029, €500M 7.875% notes due 2031, $600M 7.875% notes due 2029, $500M 8.125% notes due 2031.
Teva reports FY2022 GAAP loss $2.12, non-GAAP EPS $2.52; Q4 rev $3.9B; guides 2023 lower
Full-year 2022 revenues $14.9B (-6% YoY); GAAP diluted loss per share $2.12; non-GAAP diluted EPS $2.52.
Francis to receive $1.6M base salary, 150% target bonus, and $9M annual equity (70% PSU, 30% RSU).
Teva Q3 revenue falls 8% to $3.6B; non-GAAP EPS $0.59 flat; opioid settlement progress
Revenue $3.595B (-8% YoY, -2% in local currency); GAAP EPS $0.05; non-GAAP EPS $0.59 (flat YoY).
Teva Q2 revenue $3.8B, non-GAAP EPS $0.68; reaches $4.25B opioids settlement in principle
Revenue $3.8B (-3% YoY, +1% local currency); GAAP loss $0.21, non-GAAP EPS $0.68 vs $0.59 prior year
Teva Q1 GAAP loss $0.86/share; revenue down 8%; cuts FY revenue guidance
GAAP diluted loss per share $0.86 vs. income $0.07 in Q1 2021; non-GAAP EPS $0.55 vs. $0.63.
Teva reports FY 2021 revenue down 5% to $15.9B; GAAP EPS $0.38; Q4 GAAP loss
FY 2021 revenues $15.9B, down 5% YoY; GAAP diluted EPS $0.38 vs -$3.64 in 2020.
Teva issues €2.6B and $2B sustainability-linked notes; upsizes tender offer to $4B
€1.1B 3.750% notes due 2027 and €1.5B 4.375% notes due 2030 issued.
Teva prices $5B equivalent sustainability-linked notes; proceeds to repay debt
Teva upsized and priced €1.1B 3.75% notes due 2027, €1.5B 4.375% notes due 2030, $1B 4.75% notes due 2027, and $1B 5.125% notes due 2029.
Israeli court rules Teva owes ~$350M in back taxes for 2008-2011; Teva to appeal
Israeli Central District Court ruled against Teva on tax assessments for 2008-2011, finding ~$350 million liability.
Teva Q3 revenues $3.9B (-2% YoY), non-GAAP EPS $0.59 vs $0.58; reaffirms FY guidance
GAAP diluted EPS $0.26 on net income $292M (vs loss $4.349B in Q3 2020).
Teva Q2 2021: Revenue $3.9B, GAAP EPS $0.19, Non-GAAP EPS $0.59; guides revenue lower
Revenue of $3.9B (up 1% YoY); GAAP diluted EPS $0.19 (vs $0.13 Q2 2020); Non-GAAP diluted EPS $0.59 (vs $0.55).
the Board elected Mr. Chen Lichtenstein to serve as a member of the Board, effective December 1, 2024
Mr. Eric Drapé, Executive Vice President, Global Operations, will be leaving Teva Pharmaceutical Industries Ltd.
Mr. Matthew Shields has been appointed as Executive Vice President, Global Operations of Teva and a member of Teva Executive Management, effective June 3, 2024.
Dr. Sven Dethlefs, Executive Vice President, North America Commercial, will be leaving Teva.
Ms. Christine Fox will be appointed as Executive Vice President, U.S. Commercial.
On August 1, 2023, at a meeting of the Board of Directors (the “Board”) of Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”), the Board elected Prof. Varda Shalev to serve as a member of the Board, effective September 1, 2023, until Teva’s 2024 annual meeting of shareholders.
On May 8, 2023, Jean-Michel Halfon informed Teva Pharmaceutical Industries Ltd. (“Teva”) that in light of personal reasons, he will resign from Teva’s Board of Directors (“Board”), effective immediately.
In order to facilitate an orderly transition, Kåre Schultz and the Company’s Board of Directors have mutually agreed that Mr. Schultz will retire from his current positions as President and Chief Executive Officer, and a member of the Board of Directors, effective December 31, 2022.
On November 21, 2022, Teva Pharmaceutical Industries Ltd. (the “Company”) announced that its Board of Directors had appointed Richard Francis to become the Company’s President and Chief Executive Officer, effective January 1, 2023.
Dr. Hafrun Fridriksdottir, Executive Vice President, Global R&D, will be leaving Teva Pharmaceutical Industries Ltd.
Amir Weiss, currently Vice President of Finance and Corporate Controller, was promoted to Senior Vice President and Chief Accounting Officer, effective November 24, 2021.
Andrew Weil, Teva’s Chief Accounting Officer, will step down from his role as Chief Accounting Officer, effective November 24, 2021.
Max materiality 0.85 · Median 0.70 · Most common event earnings